GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Frequently asked questions
What sector does GH RESEARCH PLC DL-025 (1KA) operate in?
GH RESEARCH PLC DL-025 belongs to the Healthcare sector and operates in the Biotechnology industry.
What is GH RESEARCH PLC DL-025 (1KA) current stock price?
As of the latest data, GH RESEARCH PLC DL-025 stock price is €20.00, with a previous close of €20.00.
What is GH RESEARCH PLC DL-025 (1KA) current market capitalization?
GH RESEARCH PLC DL-025 market cap is approximately 1.37 billion.
What is GH RESEARCH PLC DL-025 (1KA) Earnings Per Share (EPS)?
The trailing EPS is -€0.87.
What is GH RESEARCH PLC DL-025 (1KA) EBITDA?
GH RESEARCH PLC DL-025 EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -13.18 million.
Does GH RESEARCH PLC DL-025 (1KA) pay dividends?
No. GH RESEARCH PLC DL-025 does not pay a dividend.
When is GH RESEARCH PLC DL-025 (1KA) next earnings report?
GH RESEARCH PLC DL-025 is expected to release its next earnings report on September 30, 2026.
What is GH RESEARCH PLC DL-025 (1KA) beta (volatility) score?
GH RESEARCH PLC DL-025 has a beta of 1.279, suggesting it is more volatile than the market.
